Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| IBERE PHARMACEUTICALSIBER · Entity 141979 | Director | February 25, 2021 | February 26, 2021 |
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Director | June 27, 2017 | June 27, 2017 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
IBERE PHARMACEUTICALS
Report date February 25, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-25 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252863) (the "Registration Statement") under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares, par value $0.0001 per share, will automatically be converted into shares of Class A ordinary shares, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis subject to adjustment pursuant to certain anti-dilution rights described therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252863) (the "Registration Statement") under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares, par value $0.0001 per share, will automatically be converted into shares of Class A ordinary shares, par value $0.0001 per share, at the time of the issuer's initial business combination, on a one-for-one basis subject to adjustment pursuant to certain anti-dilution rights described therein.
Mersana Therapeutics, Inc.
Report date June 27, 2017 · Filed June 27, 2017
This filing explicitly reported no securities owned.
NextCure, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2036-06-17 | Direct | 2,340 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 2,340 · Balance 2,340 F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Gritstone bio, Inc.
Report date April 04, 2025 · Filed April 09, 2025
Section 16 reporting ended · disclosed 2025-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Other · Disposed 51,800 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.76 · Expires 2034-06-16 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-04 · Other · Disposed 51,800 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F3: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 · Expires 2031-06-17 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-04 · Other · Disposed 19,000 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2030-06-17 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-04 · Other · Disposed 12,500 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The options are fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2029-09-11 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-04-04 · Other · Disposed 15,942 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The options are fully vested. |
| Stcok Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2032-06-16 | Direct | 0 |
Reported balance
After 2025-04-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-04 · Other · Disposed 19,000 · Balance 0 F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2: The options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.
F2: The options are fully vested.
F3: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:15 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0000905148-26-003045 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340 Underlying: Common Stock · 2,340 shares Expires 2036-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:45 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 59,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001610717-26-000274 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:31 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000905148-25-002245 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2035-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:17 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000211 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStock Option (Right to Buy) · Derivative | 15,942 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 6 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,942 shares Expires 2029-09-11 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 5 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-06-17 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 4 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2031-06-17 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStcok Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 3 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2032-06-16 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStock Option (Right to Buy) · Derivative | 51,800 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 2 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,800 shares Expires 2034-06-16 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F3 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| April 04, 2025 Filed Apr 9, 2025 00:58 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | OtherStock Option (Right to Buy) · Derivative | 51,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001415889-25-010438 · form4-04092025_120421.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,800 shares Expires 2033-06-15 F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value. F2 · derivative.exercise_date: The options are fully vested. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:04 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-24-001767 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:52 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 51,800 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001415889-24-017701 · form4-06202024_090646.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,800 Underlying: Common Stock · 51,800 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:33 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000244 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:30 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001140361-23-031189 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:52 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 51,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0000899243-23-016161 · doc4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,800 Underlying: Common Stock · 51,800 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000178 · form4.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | PurchaseCommon Stock | 5,000 | $1.55 | $7,750.00 |
DisclosureSEC source: 0001140361-23-015503 · form4.xml · nonDerivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,142 Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 21:23 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001567619-22-013367 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2032-06-22 F1 · derivative.exercise_date: The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:33 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001567619-22-013258 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013070 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:13 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001567619-21-012668 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| June 18, 2021 Filed Nov 19, 2021 22:10 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0001567619-21-020865 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:44 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012367 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:34 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.66 | $0.00 |
DisclosureSEC source: 0001567619-20-012486 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:09 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012301 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:37 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000880 · edgar.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:19 UTC | Gritstone bio, Inc. GRTS · Entity 80946 | GrantStock Option (Right to Buy) · Derivative | 15,942 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001567619-19-018265 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,942 Underlying: Common Stock · 15,942 shares Expires 2029-09-12 F1 · derivative.exercise_date: The option shall vest and become exercisable in substantially equal monthly installments for three years from the date of grant, subject to continued service through each applicable vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 18:02 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013823 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:23 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000893 · edgar.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| May 01, 2019 Filed May 3, 2019 00:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0001567619-19-009691 · doc1.xml · derivative · entry 1 Jones Elaine V · CIK 0001296907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2029-04-30 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from May 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.